Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
immunology
pathology
urology
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
accepted:
21
04
2020
entrez:
26
5
2020
pubmed:
26
5
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
Assessment of the immune status of muscle-invasive bladder cancer (MIBC) has previously shown to be prognostically relevant after treatment with curative intent. We conducted this study to develop a clinically applicable immune gene expression assay to predict prognosis and adjuvant chemotherapy benefit. Gene expression of The gene expression signature of The gene expression signature of
Sections du résumé
BACKGROUND
Assessment of the immune status of muscle-invasive bladder cancer (MIBC) has previously shown to be prognostically relevant after treatment with curative intent. We conducted this study to develop a clinically applicable immune gene expression assay to predict prognosis and adjuvant chemotherapy benefit.
PATIENTS AND METHODS
Gene expression of
RESULTS
The gene expression signature of
CONCLUSION
The gene expression signature of
Identifiants
pubmed: 32448798
pii: jitc-2019-000162
doi: 10.1136/jitc-2019-000162
pmc: PMC7253053
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: RW is founder and CEO of STRATIFYER Molecular pathology.
Références
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Nat Rev Immunol. 2002 Jun;2(6):401-9
pubmed: 12093006
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Sci Rep. 2018 May 10;8(1):7485
pubmed: 29748589
Oncotarget. 2018 Feb 19;9(19):15001-15014
pubmed: 29599921
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
J Exp Med. 2016 Dec 12;213(13):2835-2840
pubmed: 27903604
Cancer Treat Rev. 2017 Mar;54:58-67
pubmed: 28214651
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Clin Oncol. 2018 Dec 1;36(34):3353-3360
pubmed: 30343614
Cancer Immunol Immunother. 2018 Mar;67(3):403-412
pubmed: 29150702
Bladder Cancer. 2016 Jan 7;2(1):37-47
pubmed: 27376123
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
Eur J Cancer. 2019 Jun;114:76-88
pubmed: 31075727
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Nat Rev Immunol. 2004 Sep;4(9):675-87
pubmed: 15343367
Cancer Immunol Res. 2019 Jun;7(6):923-938
pubmed: 30988029
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
J Pathol. 2017 May;242(1):113-125
pubmed: 28195647
Eur J Cancer. 2019 Jan;106:234-243
pubmed: 30528808
Nat Rev Immunol. 2018 Aug;18(8):485-497
pubmed: 29789755
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Oncoimmunology. 2015 Dec 29;5(5):e1122160
pubmed: 27467919
Eur Urol. 2019 Jul;76(1):59-68
pubmed: 30712971
Sci Rep. 2018 Dec 6;8(1):17693
pubmed: 30523270
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Cell. 2017 Nov 30;171(6):1284-1300.e21
pubmed: 29195073
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Oncotarget. 2016 Jul 12;7(28):44288-44298
pubmed: 27329588
Urol Oncol. 2014 Aug;32(6):791-7
pubmed: 24794251